TY - JOUR
T1 - Expression of the interleukin-2 receptor (Tac antigen/CD25) in hematologic neoplasms
AU - Erber, W. N.
AU - Mason, D. Y.
PY - 1988/1/1
Y1 - 1988/1/1
N2 - The expression of interleukin-2 (IL-2) receptor (CD25) has been investigated in 165 cases of hematologic neoplasia by alkaline phosphatase-antialkaline phosphatase (APAAP) labeling of cell smears using two monoclonal anti-IL-2 receptor antibodies (anti-Tac and DAKO-IL2-R). IL-2 receptor was found in 2 of 16 (13%) T-cell malignancies (1 T-ALL, 1 Sezary syndrome). In contrast, among B-cell disorders, IL-2 receptor was expressed in the majority of hairy cell leukemia cases (14 of 16, i.e., 88%) and in a smaller proportion of cases of common acute lymphoblastic leukemia (7 of 44, i.e., 16%), B-cell chronic lymphocytic leukemia (8 of 20, i.e., 40%), B-cell prolymphocytic leukemia (3 of 5), and B-cell lymphoma (3 of 8). In addition, IL-2 receptor was present on the neoplastic cells in some cases of acute myeloid leukemia (6 of 44, i.e., 14%) and acute undifferentiated leukemia (4 of 7). IL-2 receptor (Tac antigen) expression is thus found across the spectrum of hematologic neoplasms and is not restricted to T-cell disorders. The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear.
AB - The expression of interleukin-2 (IL-2) receptor (CD25) has been investigated in 165 cases of hematologic neoplasia by alkaline phosphatase-antialkaline phosphatase (APAAP) labeling of cell smears using two monoclonal anti-IL-2 receptor antibodies (anti-Tac and DAKO-IL2-R). IL-2 receptor was found in 2 of 16 (13%) T-cell malignancies (1 T-ALL, 1 Sezary syndrome). In contrast, among B-cell disorders, IL-2 receptor was expressed in the majority of hairy cell leukemia cases (14 of 16, i.e., 88%) and in a smaller proportion of cases of common acute lymphoblastic leukemia (7 of 44, i.e., 16%), B-cell chronic lymphocytic leukemia (8 of 20, i.e., 40%), B-cell prolymphocytic leukemia (3 of 5), and B-cell lymphoma (3 of 8). In addition, IL-2 receptor was present on the neoplastic cells in some cases of acute myeloid leukemia (6 of 44, i.e., 14%) and acute undifferentiated leukemia (4 of 7). IL-2 receptor (Tac antigen) expression is thus found across the spectrum of hematologic neoplasms and is not restricted to T-cell disorders. The explanation for the expression of the IL-2 receptor by such a variety of different hematologic malignancies remains unclear.
UR - http://www.scopus.com/inward/record.url?scp=0023880985&partnerID=8YFLogxK
U2 - 10.1093/ajcp/89.5.645
DO - 10.1093/ajcp/89.5.645
M3 - Article
C2 - 3128947
AN - SCOPUS:0023880985
SN - 0002-9173
VL - 89
SP - 645
EP - 648
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 5
ER -